Study of GS-0415 in People with HIV
Part of Infections clinical trials.
This study tests a new drug, GS-0415, for people with HIV. The study will see if this drug can help control the virus. Participants will continue taking their regular HIV medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been on the same HIV medication for at least a year.
- Your HIV levels have been undetectable for at least a year.
- Your CD4 count (a measure of immune health) is stable and not too low.
- You do not have active hepatitis B or C.
- You have not had severe skin reactions or allergies to medications in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests an experimental medication in healthy volunteers to see how it is processed by the body and whether it is safe. You may not receive direct benefit, but your participation helps find better treatments for people with HIV.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.